Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Consolidated China Revenue: $1,939M in FY2025, down 64.7% from a year earlier.
Latest, FY2025
1,939
Period ended Dec 31, 2025
Change on a year earlier
-64.7%
5,494 in FY2024
History
10 years
Since FY2016
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Postgres DB segment_values.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated China Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,939 | -64.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 5,494 | -19.2% | Form 10-K (filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 6,802 | +31.0% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 5,191 | +18.6% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 4,378 | +59.1% | Form 10-K (filed 2022-02-25) ↗ |
| FY2020 | Dec 31, 2020 | 2,751 | +26.2% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 2,180 | -0.2% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 2,184 | +37.7% | Form 10-K (filed 2019-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 1,586 | +10.5% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 1,435 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). Merck Consolidated China Revenue ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db-geo-cn-rev
See every metric in the Merck KPI table. Data updated Oct 26, 2026.